News
-
HHS Warns Providers About a New Cybercriminal Gang Attacking the Healthcare Sector
HHS issued an alert warning providers about Rhysida, a ransomware gang that recently begun launching attacks on healthcare organizations. The group deploys its ransomware primarily through phishing attacks or the exploitation of legitimate cybersecurity tools.
-
Daybreak Health Snags $13M For School-Based Mental Health Services
Daybreak Health — a startup that partners with school districts to provide children with virtual mental health services — recently closed a $13 million Series B funding round. The company has partnered with more than 60 public school districts since it began providing care in 2019.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Consumer / Employer, Health Tech
Scripta Insights Partners with Mark Cuban Cost Plus Drug Company
Through Scripta Insights’ app, members of its customers can input the medications they’re taking, and the company will provide a savings report that will show different options on how they can save on their prescriptions. Starting in 2024, Cost Plus Drugs may show up as an option in the savings report.
-
Novo Nordisk’s Wegovy Posts Trial Data Supporting the Drug as Way to Lower Heart Risks
Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
-
Novel Social Anxiety Disorder Drug’s Data Relieve Stress on a Beleaguered Biotech
Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder. Vistagen’s stock price rocketed skyward on the results, which support progression to another Phase 3 study.
-
How Did The 3 Biggest For-Profit Hospital Chains Perform in Q2?
HCA and Tenet reported net incomes for the second quarter, while CHS posted a net loss. All three health systems found themselves in a better financial position in Q2 2023 than they were in Q2 of last year, driven in large part by declining contract labor expenses.
-
Hospitals Still Struggling to Get Back Online 4 Days After Cyberattack on Prospect Medical Holdings
Hospitals and outpatient treatment centers in at least three states are struggling to get their systems back online following a ransomware attack waged last week against parent company Prospect Medical Holdings. Some of these facilities have partially or completely halted patient care.
-
Talkiatry, NOCD Strike Partnership To Support Patients With OCD
Talkiatry and NOCD are teaming up to improve care for patients with obsessive-compulsive disorder. Talkiatry specializes in medication management, while NOCD specializes in Exposure and Response Prevention therapy.
-
Astellas Drug Acquired in $5.9B Deal Wins FDA Approval in Vision-Loss Disorder
Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy. The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
The Evolution of Patient-Centered Clinical Trial Design
Clinical trial design will be one of the topics discussed at the upcoming INVEST Digital Health conference in Dallas on October 26. THREAD Clinical Trial Design Director Noah Goodson highlighted some of the milestones the sector has seen in recent years.
-
Health Tech, Hospitals, Pharmacy
Which Drugs Are Driving Next Year’s 3.42% Increase in Hospital Pharmacy Spend?
Hospitals’ pharmacy spending is projected to rise by 3.42% next year, according to a new report. Specialty drugs, including Ozempic and Humira, as well as neurology medications are the primary drivers of this increase in pharmacy expenses.
-
Drug and Digital Technologies Are Part of NIH’s Long Covid Clinical Trial Plans
Long Covid continues to afflict patients and mystify clinicians. The National Institutes of Health is trying to identify potential treatments and it is launching a series of clinical trials that will assess a wide range of therapeutic interventions.
-
Sage, Biogen Drug Is Now the First Approved Oral Med for Postpartum Depression
Sage Therapeutics’ Zurzuvae is the biotech’s second FDA approved product for postpartum depression, following the 2019 nod for IV-infused Zulresso. But in a blow to the multi-billion dollar partnership between Sage and Biogen, Zurzuvae did not win an additional approval in major depressive disorder.
-
Geisinger Launches Heart Failure Monitoring Program Using Bodyport’s Smart Scale
Geisinger is launching a pilot program in partnership with virtual heart failure monitoring startup Bodyport. About 200 of the health system’s heart failure patients will be using Bodyport’s cardiac scale at home — the scale uses sensors to measure a person’s metrics of heart function and body fluid status after they stand on it for about 20 seconds.
-
The Importance of Early Bariatric Patient Engagement
Engaging with patients in the early stages of their bariatric journey allows providers to ultimately understand and support their patient’s unique motivational, emotional, and intellectual drivers. Providers can use these drivers to help empower positive health outcomes.
-
Consumer / Employer, Health Tech
Hims & Hers Dips Into Men’s Cardiovascular Health
Hims & Hers can now provide treatment to men for cardiovascular issues, the company recently announced. This treatment combines sexual health and heart health together in a single pill.
-
Novartis Pays Ionis $60M to Expand Alliance on a Hot Target for Cardio Drugs
Novartis and Ionis Pharmaceuticals, already partners in cardiovascular disease R&D, are expanding their alliance to see if they can develop a next-generation therapy offering efficacy and dosing advantages. But competitors are already in the mix with programs addressing the same cardiovascular disease target.
-
Signify Health Unveils Chronic Kidney Disease Evaluation
Home care company Signify Health announced Tuesday that it added an in-home kidney health evaluation to its platform. Based on the results of the evaluation, the company can refer patients to their primary care physician or a specialist if they’re in need of further treatment.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
